Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Brontictuzumab||OMP-52M51||NOTCH1 Antibody 2||Brontictuzumab (OMP-52M51) is a monoclonal antibody that binds Notch1 and prevents ligand interaction and pathway activation, which may inhibit angiogenesis and tumor growth (PMID: 23774673, PMID: 31616059, PMID: 29726923).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Brontictuzumab||Phase I||Actionable||In a Phase I trial, Brontictuzumab (OMP-52M51) treatment in patients with advanced selected solid tumors was well-tolerated, demonstrated target engagement, and resulted in unconfirmed partial response in 5% (2/36) of patients (both adenoid cystic carcinoma with high NICD1 expression); stable disease (SD) in 28% (10/36), with 4 patients, all with high NICD1 expression, demonstrating SD for greater than 6 months; and a median progression-free survival of 65 days (PMID: 29726923; NCT01778439).||29726923|
|NOTCH1 S1004L||adenoid cystic carcinoma||no benefit||Brontictuzumab||Preclinical - Pdx||Actionable||In a preclinical study, Brontictuzumab (OMP-52M51) did not inhibit tumor growth in a patient-derived xenograft model of adenoid cystic carcinoma harboring NOTCH1 S1004L (PMID: 27870570).||27870570|
|FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs||adenoid cystic carcinoma||predicted - resistant||Brontictuzumab||Case Reports/Case Series||Actionable||In a clinical case study, FBXW7 W606* and NOTCH1 V1721G were identified at disease progression in a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs who was treated with Brontictuzumab (OMP-52M51) (PMID: 27870570).||27870570|
|NOTCH1 act mut||breast cancer||sensitive||Brontictuzumab||Preclinical - Pdx||Actionable||In a preclinical study, Brontictuzumab (OMP-52M51) inhibited tumor growth and reduced cancer stem cells in xenograft models of tumor derived from a breast cancer patient harboring activating NOTCH1 mutations (Cancer Res 2013;73(8 Suppl):Abstract nr 3728).||detail...|
|NOTCH1 over exp||Advanced Solid Tumor||sensitive||Brontictuzumab||Phase I||Actionable||In a Phase I trial, Brontictuzumab (OMP-52M51) treatment resulted in stable disease in 43% (3/7) of advanced solid tumor patients with elevated levels of Notch1 intracellular domain (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C42).||detail...|
|NOTCH1 L1600Q NOTCH1 S2467fs||adenoid cystic carcinoma||predicted - sensitive||Brontictuzumab||Case Reports/Case Series||Actionable||In a clinical case study, a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs achieved a partial response after 2 doses of Brontictuzumab (OMP-52M51), however, his disease progressed shortly after treatment discontinuation (PMID: 27870570).||27870570|
|NOTCH1 I1680N||adenoid cystic carcinoma||predicted - sensitive||Brontictuzumab||Preclinical - Pdx||Actionable||In a preclinical study, Brontictuzumab (OMP-52M51) inhibited tumor growth in a patient-derived xenograft model of adenoid cystic carcinoma harboring NOTCH1 I1680N (PMID: 27870570).||27870570|
|NOTCH1 act mut||acute lymphoblastic leukemia||sensitive||Brontictuzumab||Preclinical - Pdx||Actionable||In a preclinical study, xenograft models of patient-derived acute lymphocytic leukemia cells harboring NOTCH1 activating muatations demonstrated better response to Brontictuzumab (OMP-52M51) compared to NOTCH1 wild-type models (PMID: 23774673).||23774673|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01778439||Phase I||Brontictuzumab||A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors||Completed||USA||0|
|NCT01703572||Phase I||Brontictuzumab||A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies||Completed||USA||0|